{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:41:30Z","timestamp":1789879290999,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Papillomavirus Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.pvr.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T21:46:20Z","timestamp":1513633580000},"page":"63-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women"],"prefix":"10.1016","volume":"5","author":[{"given":"\u00c1ngela Mar\u00eda","family":"Ruiz-Sternberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edson D.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime A.","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Lazcano-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robinson","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosires","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Revollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Uscanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Victoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Plata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Nossa","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison","family":"Fedrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misoo C.","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cashat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pvr.2017.12.004_bib1","article-title":"GLOBOCAN 2012: estimated cancer incidence","author":"International Agency for Research on Cancer","year":"2012","journal-title":"Mortal. Preval. Worldw."},{"key":"10.1016\/j.pvr.2017.12.004_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.pvr.2017.12.004_bib3","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.canep.2016.07.015","article-title":"Cervical cancer in Central and South America: burden of disease and status of disease control","volume":"44 Suppl 1","author":"Murillo","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.pvr.2017.12.004_bib4","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.ejca.2013.04.024","article-title":"Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors","volume":"49","author":"Vaccarella","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.pvr.2017.12.004_bib5","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pvr.2017.12.004_bib6","unstructured":"Pan American Health Organization (PAHO), World Health Organization (WHO), Cervical Cancer in the Americas. \u3008http:\/\/www.paho.org\/hq\/index.php?Option=com_topics&view=rdmore&cid=3673&Itemid=40936&lang=en\u3009 (accessed 11 June 2017)."},{"issue":"Suppl 5","key":"10.1016\/j.pvr.2017.12.004_bib7","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.12.004_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pcl.2015.08.004","article-title":"Global Delivery of Human Papillomavirus Vaccines","volume":"63","author":"Wigle","year":"2016","journal-title":"Pediatr. Clin. North Am."},{"key":"10.1016\/j.pvr.2017.12.004_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pvr.2017.12.004_bib10","doi-asserted-by":"crossref","first-page":"e20151968","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV After Introduction of the Vaccination Program in the United States","volume":"137","author":"Markowitz","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.pvr.2017.12.004_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pvr.2017.12.004_bib12","unstructured":"Technical Advisory Group on Vaccine-preventable Diseases of the Pan American Health Organization, Final Report of the XXIII Meeting of the Technical Advisory Group (TAG), 2015."},{"key":"10.1016\/j.pvr.2017.12.004_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.pvr.2017.12.004_bib14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pvr.2017.12.004_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pvr.2017.12.004_bib16","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3201\/eid2210.160675","article-title":"Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes","volume":"22","author":"Mesher","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pvr.2017.12.004_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pvr.2017.01.001","article-title":"Human papillomavirus (HPV) in young women in Britain: population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types","volume":"3","author":"Tanton","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.pvr.2017.12.004_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jinf.2017.01.007","article-title":"No evidence for cross-protection of the HPV-16\/18 vaccine against HPV-6\/11 positivity in female STI clinic visitors","volume":"74","author":"Woestenberg","year":"2017","journal-title":"J. Infect."},{"issue":"Suppl 11","key":"10.1016\/j.pvr.2017.12.004_bib19","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1016\/j.vaccine.2008.05.043","article-title":"Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region","volume":"26","author":"Parkin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.12.004_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.pvr.2017.12.004_bib21","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.pvr.2017.12.004_bib22","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","article-title":"Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions","volume":"51","author":"Serrano","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.pvr.2017.12.004_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pvr.2016.03.002","article-title":"Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region","volume":"2","author":"Castellsague","year":"2016","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.pvr.2017.12.004_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pvr.2017.12.004_bib25","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Efficacy, immunogenicity, and safety of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: final analyses of a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pvr.2017.12.004_bib26","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.pvr.2017.12.004_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1740774514552110","article-title":"A seamless phase IIB\/III adaptive outcome trial: design rationale and implementation challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Clin. Trials"},{"key":"10.1016\/j.pvr.2017.12.004_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cct.2015.02.009","article-title":"Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine","volume":"42","author":"Luxembourg","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.pvr.2017.12.004_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2015.1012010","article-title":"Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.pvr.2017.12.004_bib30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/21645515.2015.1009819","article-title":"Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.pvr.2017.12.004_bib31","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1016\/j.vaccine.2017.07.017","article-title":"Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine","volume":"35","author":"Guevara","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.12.004_bib32","unstructured":"World Health Organization (WHO), Guidelines to assure the quality, safety and efficacy of recombinant HPV virus-like particle vaccines. WHO\/BS\/06.2050, 2006."},{"key":"10.1016\/j.pvr.2017.12.004_bib33","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4161\/hv.29205","article-title":"Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types","volume":"10","author":"Roberts","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.pvr.2017.12.004_bib34","doi-asserted-by":"crossref","first-page":"e20154387","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 Phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.pvr.2017.12.004_bib35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/03610929808832160","article-title":"Exact power and sample size for vaccine efficacy studies","volume":"27","author":"Chan","year":"1998","journal-title":"Comm. Stat. Theory Methods"},{"key":"10.1016\/j.pvr.2017.12.004_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0952-7915(02)00367-9","article-title":"On differences between immunity and immunological memory","volume":"14","author":"Zinkernagel","year":"2002","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.pvr.2017.12.004_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries","volume":"66","author":"Kjaer","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pvr.2017.12.004_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cct.2016.10.006","article-title":"Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine","volume":"52","author":"Luxembourg","year":"2017","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.pvr.2017.12.004_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect. Agent Cancer"},{"key":"10.1016\/j.pvr.2017.12.004_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/GCO.0000000000000208","article-title":"Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination","volume":"27","author":"Lehtinen","year":"2015","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.pvr.2017.12.004_bib41","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0140-6736(16)30314-2","article-title":"Expanding the benefits of HPV vaccination to boys and men","volume":"387","author":"Schmeler","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pvr.2017.12.004_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pvr.2017.12.004_bib43","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pvr.2017.12.004_bib44","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","article-title":"Role of human papillomavirus in penile carcinomas worldwide","volume":"69","author":"Alemany","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.pvr.2017.12.004_bib45","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper","volume":"92","author":"World Health Organization (WHO)","year":"2017","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.pvr.2017.12.004_bib46","unstructured":"World Health Organization (WHO), Guide to Introducing HPV Vaccine into National Immunization Programmes. \u3008http:\/\/apps.who.int\/iris\/bitstream\/10665\/253123\/1\/9789241549769-eng.pdf?Ua=1\u3009 (accessed 15 March 2017)."},{"key":"10.1016\/j.pvr.2017.12.004_bib47","unstructured":"Global Advisory Committee on Vaccine Safety, World Health Organization (WHO), Statement on Safety of HPV Vaccines. \u3008http:\/\/www.who.int\/vaccine_safety\/committee\/GACVS_HPV_statement_17Dec2015.pdf?Ua=1\u3009, 17 December 2015 (accessed 20 June 2017)."},{"key":"10.1016\/j.pvr.2017.12.004_bib48","first-page":"21","article-title":"Global advisory committee on vaccine safety, 2-3 December 2015","volume":"91","author":"World Health Organization (WHO)","year":"2016","journal-title":"Wkly.\u00a0Epidemiol. Rec."},{"key":"10.1016\/j.pvr.2017.12.004_bib49","unstructured":"World Health Organization (WHO), WHO HPV Vaccine Communication: Special considerations for a unique vaccine. \u3008http:\/\/apps.who.int\/iris\/bitstream\/10665\/250279\/1\/WHO-IVB-16.02-eng.pdf?Ua=1\u3009 (accessed 15 March 2017)."}],"container-title":["Papillomavirus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852117300654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852117300654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:03:40Z","timestamp":1762513420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405852117300654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":49,"alternative-id":["S2405852117300654"],"URL":"https:\/\/doi.org\/10.1016\/j.pvr.2017.12.004","relation":{},"ISSN":["2405-8521"],"issn-type":[{"value":"2405-8521","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women","name":"articletitle","label":"Article Title"},{"value":"Papillomavirus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pvr.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Merck Sharp & Dohme Corp., and The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}